Genzyme maintained by Merrill at neutral

Genzyme was maintained by Merrill Lynch analyst Eric Ende at a neutral rating as the company prerecorded fourth-quarter 2005 revenue of $722 million, modestly below the analyst's estimate of $735 million. The difference was attributed to lower-than-expected sales of Cerezyme, Hectoral and Diagnostic/Genetic sales and offset by higher-than-expected Synvisc and Renagel sales. The analyst lowered earnings per share for the same quarter to $0.59 from $0.61. Shares of the Cambridge, Mass., biopharmaceutical company were down 62 cents, or 0.83%, at $74.42 on volume of 3,418,544 shares versus the three-month running average of 2,145,650 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.